

April 28, 2023

Texas DUR Board Proposed Retrospective-DUR Interventions Prepared by Amy Cully, PharmD



Agenda

Recent Interventions

- Hypertension Disease Management
- Management of Psychotropic Drugs in Adults
- Naloxone for High-Risk Patients

Recent Outcome Reports

- Combined Use of Opioids and CNS Depressants DUE 2022
- Management of Psychotropic Drugs in Pediatric Patients 2022 ۲

Potential Retro DUR Interventions

Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma




2

Recent RetroDUR Interventions

Intervention	Date Mailed	Provider Letters
Hypertension Disease Management	3/17/2023	679
Management of Psychotropic Drugs in Adults	3/22/2023	129
Naloxone in High-Risk Patients	02/17/2023	38





Recent Outcome Reports

Intervention	Date Mailed	
Combined Use of Opioids and CNS Depressants DUE 2022	4/8/2022	
Management of Psychotropic Drugs in Pediatric Patients 2022	4/28/2022	



12-Month State Savings

\$6,104.44

\$29,374.70

Recent Outcome Reports:

Combined Use of Opioids and CNS Depressants DUE 2022

Clinical Indicators	Baseline	Oct-2022	% Change
Use of opioid analgesics in combination with benzodiazepines	7	5	-28.6%
Use of opioid analgesics in combination with antipsychotics	2	1	-50.0%
Use of opioid analgesics in combinations with benzodiazepines and antipsychotics	3	2	-33.3%
Use of opioid analgesic in combination with muscle relaxants	1	1	0.0%
Use of opioid analgesics in combination with benzodiazepines and muscle relaxants	2	1	-50.0%
Use of opioid analgesics in combination with sedative hypnotics	0	0	0.0%
Use of opioid analgesics in combination with benzodiazepines, sedative hypnotics or gabapentinoids without naloxone	33	22	-33.3%
Total	48	32	-33.3%



Recent Outcome Reports:

Management of Psychotropic Drugs in Pediatric Patients 2022

Clinical Indicators	Baseline	Nov-2022	% Change
High dose: oral antipsychotics	7	4	-42.9%
Multiple (2 or more) oral antipsychotics or polypharmacy (4 or more psychotropic medications)	51	34	-33.3%
Monitoring of second-generation antipsychotics: glucose or hemoglobin A1c and lipid panel	394	295	-25.1%
Second-generation antipsychotic use with new diabetes and/or lipid lowering medication	2	1	-50.0%
Total	454	334	-26.4%



Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy(SMART) Alternative for Patients with Asthma

Purpose:

To provide prescribers with educational tools to better communicate with their patients regarding the treatment of asthma, ٠ specifically the newer SMART alternative.

Why Issue was Selected:

- The U.S. Department of Health and Human Services, Centers for Disease Control and Prevention found in 2019 that asthma accounted for 1.5 million emergency department visits.
- Both the Global Initiative for Asthma and National Heart, Lung and Blood Institute recently updated their guidelines on • asthma management and recommend the use of single maintenance and reliever therapy (SMART or MART) for some patients with asthma.
- SMART involves using one inhaler consisting of controller and reliever therapy in the form of inhaled corticosteroid (ICS) • and formoterol, whereas conventional therapy consists of using two separate inhalers, one as controller and one as reliever.
- SMART is associated with a reduced risk of acute asthma exacerbations, emergency department visits, and hospitalizations when compared to conventional therapy.



Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy(SMART) Alternative for Patients with Asthma

Setting and Population:

 Providers who have 1 or more patient(s) >/=12 years of age with a diagnosis of asthma (COPD) and CF patients are eliminated) and have filled 3 or more SABA in the last 180 days.

Type of Intervention:

• Educational letter which includes recommendations from current treatment guidelines regarding SMART.

Outcome Measures:

Outcome assessment deferred due to anticipated unavailability of claims data post intervention • since this will be mailed to providers and not regarding specific patients.





Potential RetroDUR Intervention:

Single Maintenance and Reliever Therapy (SMART) Alternative for Patients with Asthma

Performance Indicators	Number of Lette
Promote optimization of asthma therapy in patients ≥ 12 years old who may be overutilizing SABA	21



ers to Providers

14



© 2022 Conduent, Inc. All rights reserved. Conduent and Conduent Agile Star are trademarks of Conduent, Inc. and/or its subsidiaries in the United States and/or other countries.